Compare OMDA & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMDA | DRTS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | Israel |
| Employees | 943 | 121 |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 978.5M | 978.2M |
| IPO Year | N/A | N/A |
| Metric | OMDA | DRTS |
|---|---|---|
| Price | $22.99 | $13.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $21.73 | $8.67 |
| AVG Volume (30 Days) | ★ 1.1M | 784.7K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.96 | N/A |
| Revenue Next Year | $20.08 | $699.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.28 | $2.87 |
| 52 Week High | $26.92 | $14.11 |
| Indicator | OMDA | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 62.09 |
| Support Level | $14.39 | $6.59 |
| Resistance Level | $26.46 | $14.11 |
| Average True Range (ATR) | 1.00 | 0.93 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 39.23 | 67.44 |
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.